21st November 2008

PRESS RELEASE

IMPEDI MED IS RECOGNISED BY THE DELOITTE TECHNOLOGY FAST 50 PROGRAM FOR THE THIRD CONSECUTIVE YEAR

ImpediMed has been named once again in Australia’s Deloitte Technology Fast 50 awards. “Now in its eighth year, the program recognises 50 dynamic and fast growing companies who have shown sustained growth over the last three years in the Australian technology industry.”

Greg Brown, ImpediMed’s CEO commented that on behalf of all ImpediMed employees he was happy to receive the award and the attention it creates for the company.

“It is extremely gratifying to receive this award for the third time in our quest to bring BIS technology to market to help improve the quality of life of cancer survivors- in particular breast cancer survivors at risk of developing lymphoedema,” added Mr Brown.

ENDS


For further information on ImpediMed contact:

Greg Brown  Impedimed CEO  +61-7-3860-3700
Stephanie Paul  Phillips Group  +61-7-3230-5000 or +61-418-753-062
About ImpediMed
ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients. For more information visit www.impedimed.com.